novoMEDLINK™ Informational SMS/MMS Terms of Use

Last Updated Feb 22, 2024 (effective date)

Agreement Generally: Acceptance. These “Terms of Use” (the “Agreement” or “Terms of Use”) are between you and the Novo Nordisk’s novoMEDLINK™ Informational SMS/MMS (“NML Informational SMS/MMS,” “we,” “us,” or “our”). “You” means you personally. This Agreement sets forth the terms and conditions upon which we make available the NML Informational SMS/MMS contents to you.

Please note these Terms of Use govern only the NML Informational SMS/MMS, and not any other service, program, or website. By opting to receive the NML Informational SMS/MMS, you are agreeing to these Terms of Use. By receiving the NML Informational SMS/MMS, you affirm that you are a U.S. resident, 18 years of age or older, a licensed healthcare provider, qualify for the NML Informational SMS/MMS, and expressly consent to receive communications from Novo Nordisk or its partners in connection with the NML Informational SMS/MMS.

For more information about data use and collection, please read the most recent version of Novo Nordisk’s Privacy Notice https://www.novonordisk-us.com/disclaimer-privacy.html. PLEASE READ THESE TERMS OF USE CAREFULLY BEFORE AGREEING TO RECEIVE THE NML INFORMATIONAL SMS/MMS.

IF YOU DO NOT AGREE TO THESE TERMS OF USE, YOU CANNOT RECEIVE OR PARTICIPATE IN THE NML INFORMATIONAL SMS/MMS.
Eligibility. To participate in the NML Informational SMS/MMS, you must be a resident of the United States and 18 years of age or older and be a licensed healthcare provider in the United States, i.e., able to register for Novo Nordisk’s novoMEDLINK™ platform. Novo Nordisk reserves the right to require you to prove that you meet this eligibility criteria. THE novoMEDLINK™ SMS/MMS ARE NOT INTENDED FOR PATIENTS, CAREGIVERS, OR ANY NON-LICENSED HEALTHCARE PROVIDER.
Modifications to Terms of Use. You agree that we may modify these Terms of Use and that such modifications shall become effective immediately upon posting of the modified Terms of Use to our website or otherwise notifying you of an update through the NML Informational SMS/MMS. If you do not accept the modifications, then you must cease using the NML Informational SMS/MMS. The Terms of Use contain the date of posting at the top of the first page.
Permission to Use NML Informational SMS/MMS; Limitations on Use of the NML Informational SMS/MMS. Subject to your acceptance and while you remain in compliance with the Terms of Use, we grant you a limited, revocable, non-exclusive, non-transferable license to use the NML Informational SMS/MMS solely and exclusively for your own professional use and not for any other purpose. This license is solely and exclusively for your benefit as a healthcare provider. All other uses of the NML Informational SMS/MMS are prohibited.
Content. All information available in or provided through the NML Informational SMS/MMS is collectively referred to in these Terms as the “Content.” The Content will include status updates on resources ordered on novoMEDLINK™, including, but not limited to samples, and may include reminder messages on your previously started, but unfinished, orders on novoMEDLINK™. Content will also include updates on when resources and/or additional Content becomes available on novoMEDLINK™ that may be beneficial to you as a healthcare provider. You may access, view, use, display, and download the Content, but you do not receive any ownership in or to the Content or any copies thereof. You may not sell, give, reproduce, create derivative works of, publicly display, or otherwise distribute the Content to anyone other than your physician(s) or caregiver(s). All rights not expressly granted herein are reserved. Novo Nordisk assumes no responsibility for the accuracy or appropriateness of any information provided by you through the NML Informational SMS/MMS.
Communication Options. To opt-in to the NML Informational SMS/MMS, you must first elect to receive NML Informational SMS/MMS in your novoMEDLINK™ account. To login to your novoMEDLINK™ account, click here. Once you do that, you will receive an initial text message confirming your election and then must text YES to finalize your opt-in to start receiving NML Informational SMS/MMS messages. If you finalize your opt-in correctly, a confirmation message will be sent to your phone number followed by a welcome message. By choosing to enroll in the NML Informational SMS/MMS, you agree to receive automated, one-way informational text messages related to novoMEDLINK™ Content as noted above. However, specific words will trigger an automated response, as noted below. We do not guarantee that the NML Informational SMS/MMS communications will be received and are not responsible for lost or misdirected communications.

For additional customer support, you can text “HELP” to 84632 or call 800-727-6500.

Text back any of the following commands to 84632 to customize your text message experience:

STOP or QUIT - stop all text messages
START - re-start text messages
Opt-Out Options. You can opt out of the NML Informational SMS/MMS by sending a reply text stating “STOP” or “QUIT” or “END” or “CANCEL” or “UNSUBSCRIBE” to 84632. You will receive an opt-out confirmation text message immediately and will be fully opted-out of the NML Informational SMS/MMS Program at that point. This will only opt you out of the specific messaging program associated with the NML Informational SMS/MMS Program.

PLEASE NOTE that opting out of the NML Informational SMS/MMS Program does not unsubscribe and/or opt you out of any future communications from Novo Nordisk or its partners that you may have previously signed up for separate and apart from the NML Informational SMS/MMS Program. Please follow instructions specific to those other, non-marketing communications to opt-out. You may opt out of marketing communications with Novo Nordisk or its partners, by clicking the “Unsubscribe” link within any email you receive from Novo Nordisk or its partners, by calling 800-727-6500, clicking here, or by sending Novo Nordisk a letter containing your name, email address, and phone number, to Novo Nordisk, 800 Scudders Mill Road, Plainsboro, New Jersey 08536.
Text Messaging. If you choose to enroll in the NML Informational SMS/MMS, the following terms apply:
1. Text Message Frequency. The NML Informational SMS/MMS’s message frequency will vary but will be recurring. These recurring messages will include reminder text messages that will provide you a direct link to your previously started, but unfinished, resources order on novoMEDLINK™ plus a one-time reminder text four (4) weeks after your initial sample order to order additional samples as needed. This one time reminder related to sample ordering will continue four (4) weeks after you order more samples. Please be aware that Novo Nordisk brands and services may have separate text messaging programs. The total number of text messages you receive from Novo Nordisk or its partners, therefore, may vary based on the number of Novo Nordisk text messaging programs for which you sign-up to receive messages.
2. Cost. You will not be charged any fee from Novo Nordisk or its partners in connection with the NML Informational SMS/MMS to receive automated text messages. However, Novo Nordisk encourages you to check with your mobile service provider to see what other message and data rates may apply, including any applicable roaming charges. Novo Nordisk is not responsible for any fees or charges from any carrier or service provider related to the NML Informational SMS/MMS communications.
3. SMS Supported Carriers. The following US carriers are supported:
  1. Major Carriers: AT&T, Verizon Wireless, Sprint, and T-Mobile USA.
  2. Minor Carriers: Aio Wireless, Alaska Communications Systems (ACS), Appalachian Wireless (EKN), Bluegrass Cellular, Boost Mobile, Carolina West Wireless, CellCom, Cellular One of East Central IL (ECIT), Cellular One of Northeast Arizona, Cellular One of Northeast Pennsylvania, Chariton Valley Cellular, Cricket, Coral Wireless (MobiPCS), Cross, C-Spire (CellSouth), Duet IP (Maximum Communications New Core Wireless), Element Mobile (Flat Wireless), Epic Touch (Elkhart Telephone), GCI, Golden State, Google Voice, Hawkeye (Chat Mobility), Hawkeye (NW Missouri),Illinois Valley Cellular, Inland Cellular, iWireless (Iowa Wireless), Keystone Wireless (Immix Wireless/PC Man), Metro PCS, Mosaic (Consolidated or CTC Telecom), MTA Communications, MTPCS (Cellular One Nation), Nex-Tech Wireless, Panhandle Communications, Peoples Wireless, Pine Cellular, Pioneer, RINA, Sagebrush Cellular (Nemont), SI Wireless/Mobile Nation, Simmetry (TMP Corporation), SouthernLinc, SRT Wireless, Thumb Cellular, Union Wireless, United Wireless, U.S. Cellular, Viaero Wireless, Virgin Mobile, and West Central (WCC or 5 Star Wireless).
4. MMS Supported Carriers. The following US carriers are supported for the NML Informational SMS/MMS Program: AT&T, Verizon Wireless, T-Mobile USA/Sprint, and US Cellular. All other US carriers do not support MMS. If you do not have one of the supported US carriers, you will not be able to receive the NML Informational SMS/MMS Program. If that is the case, you will receive an error message.
5. Your Mobile Telephone Number. You represent that you are the account holder or authorized user for the mobile telephone number you opt-in to receive messages for the NML Informational SMS/MMS.
6. Access or Delivery to Mobile Network is Not Guaranteed. Delivery of information and content to a mobile device is not guaranteed and may fail due to a variety of circumstances or conditions. Alerts sent via text message may not be delivered if the mobile phone is not in range of a transmission site, or if sufficient network capacity is not available at a particular time. Even within a coverage area, factors beyond the control of the wireless carrier may interfere with message delivery, including the customer's equipment, terrain, proximity to buildings, foliage, and weather. Novo Nordisk will not be held responsible for any delays in the receipt of any text messages as delivery is subject to effective transmission from your mobile service provider or network operator. You understand and acknowledge that network services, including but not limited to mobile network services, are outside of Novo Nordisk’s control. Note that there may be data or message fees imposed by your carrier or service provider if you choose to receive text messages from the NML Informational SMS/MMS.
Privacy & Security. To enroll in the NML Informational SMS/MMS Program, you must provide us with your phone number via your novoMEDLINK™ account. We require this information in order to communicate with you, provide you with the NML Informational SMS/MMS Program, and to send you NML Informational SMS/MMS Program materials as noted above. Your information will be shared between Novo Nordisk and its service providers who support the NML Informational SMS/MMS Program in accordance with applicable laws. Novo Nordisk and its service providers may share information that does not individually identify you without restriction in accordance with applicable laws. Novo Nordisk understands and values the importance of your privacy. In accordance with these Terms of Use, Novo Nordisk may use your information for program improvements, quality monitoring, data and analytics for Novo Nordisk commercial purposes, and future Novo Nordisk marketing communications (including branded or unbranded emails, text messages, or direct mail). For more information on how we collect and use your information, please read our full Privacy Statement https://www.novonordisk-us.com/disclaimer-privacy.html.
Security. By enrolling in the NML Informational SMS/MMS Program, you understand that Novo Nordisk is not a “Covered Entity” or “Business Associate” under the Health Insurance Portability and Accountability Act Privacy Rule (or “HIPAA”). By releasing any personal information to Novo Nordisk, you acknowledge that this information will not be protected by HIPAA but will be protected by reasonable technical and security measures.
NOT MEDICAL ADVICE. Any messages contained in the NML Informational SMS/MMS Program are not meant to be medical in nature. OUR CONTENT AND COMMUNICATIONS ARE NOT INTENDED TO BE A REPLACEMENT OR SUBSTITUTE FOR PROFESSIONAL MEDICAL ADVICE. THE CONTENT AND COMMUNICATIONS DO NOT CONSTITUTE MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT. You understand that Novo Nordisk does not endorse any particular physician or health care provider for the treatment of any specific medical condition. You further understand that the NML Informational SMS/MMS is not a means to communicate product issues or negative side effects to Novo Nordisk. You are encouraged to report negative side effects of prescription drugs to the FDA at www.fda.gov/medwatch, or by phone at 1-800-FDA-1088. Novo Nordisk does not monitor or record the novoMEDLINK™ SMS/MMS.
Prohibited Activity. You will not: (a) access or attempt to access the NML Informational SMS/MMS or any part thereof that you are not authorized to access or through any means that you are not authorized to use; (b) disrupt or interfere with the security of, or otherwise cause harm to the NML Informational SMS/MMS, systems, resources, accounts, passwords, servers or networks connected to or accessible through the NML Informational SMS/MMS or any affiliated or linked websites or access or use the NML Informational SMS/MMS in any manner that could damage, disable, overburden, or impair any server or network used by us in connection with the Informational SMS/MMS; (d) use the NML Informational SMS/MMS in any manner that infringes upon or violates any intellectual property rights or other rights or interest of any party or otherwise constitutes pornography, defamation, harassment, bullying, predatory behavior, false and deceptive advertising, or hate speech; (e) submit any software, programs, or files via the novoMEDLINK™ SMS/MMS that are harmful or disruptive of another’s equipment, software, or other property, including any corrupted files, time bombs, Trojan Horses, viruses, and worms; (f) disrupt, interfere with, or inhibit any other user from using and enjoying the NML Informational SMS/MMS; (g) violate any applicable laws or regulations related to the access to or use of the NML Informational SMS/MMS, and/or engage in any activity prohibited by the Terms of Use; (h) compile, use, download, or otherwise copy any materials available on the NML Informational SMS/MMS (except as expressly permitted), or transmit, provide, or otherwise distribute (whether or not for a fee) such materials to any third party; (i) use, or allow anyone else to use, any robot, spider, or other such programmatic or automatic device, including but not limited to automated dial-in or inquiry devices, to obtain information from the Site or otherwise monitor or copy any portion of the NML Informational SMS/MMS Program; (j) frame, mirror, or use framing techniques on any part of the NML Informational SMS/MMS without our express prior written consent; (k) make any use of, or allow anyone else to make any use of, data extraction, scraping, mining, or other data gathering tools, or create a database by systematically downloading or storing the NML Informational SMS/MMS, or any portion thereof, or otherwise scrape, collect, store, or use the NML Informational SMS/MMS except pursuant to the limited license granted by the Terms of Use; (l) modify, adapt, translate, reverse engineer, decompile, or disassemble any portion of the NML Informational SMS/MMS; or (m) remove any copyright, trademark, or other proprietary rights notice from the NML Informational SMS/MMS. These examples of prohibited conduct are illustrative and are not exhaustive.

TO THE MAXIMUM EXTENT AUTHORIZED BY LAW WE RESERVE THE RIGHT, BUT DISCLAIM ANY OBLIGATION WHATSOEVER, TO MONITOR OUR SITE AND YOUR COMPLIANCE WITH THIS SECTION AND WITH THE TERMS OF USE AS A WHOLE.
Termination of NML Informational SMS/MMS. Novo Nordisk may suspend or terminate your use of the NML Informational SMS/MMS if Novo Nordisk believes you are in breach of these Terms of Use. Your receipt of NML Informational SMS/MMS communications is also subject to termination in the event that your telephone or network service terminates or lapses. Novo Nordisk reserves the right to modify or discontinue, temporarily or permanently, all or any part of the NML Informational SMS/MMS with or without notice. You assume sole responsibility for the proper use and scheduling of any medications, treatments, and procedures related to your health care and disease management.
Assignment. You may not assign any of your rights or obligations hereunder, whether by operation of law or otherwise, without our prior written consent. Notwithstanding the foregoing, we may freely assign the Terms of Use, and the rights and obligations therein, without your consent, including but not limited to, in connection with a merger, acquisition, corporate reorganization, or sale of all or substantially all of our assets. Subject to the foregoing, the Terms of Use shall bind and inure to the benefit of the parties, their respective successors and permitted assigns.
Entire Agreement. This Agreement, including the documents incorporated herein by reference, is the entire understanding and agreement between the NML Informational SMS/MMS and you with respect to the subject matter hereof.
Miscellaneous. The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision. To the event that any provision of this Agreement is found to be invalid or unenforceable, this Agreement shall be construed in accordance with its terms as if the invalid or unenforceable provision was not contained therein. No delay or failure by the NML Informational SMS/MMS to enforce any provision of this Agreement shall be a waiver of any of our rights under this Agreement.